· Vision and Mission
Our company has been named on Forbes’ List of Most Promising Small and Medium-Sized Enterprises.
Release time:
2014-01-14 15:29
On January 6, Forbes China released its “List of China’s Most Promising Small and Medium-Sized Enterprises” for the tenth consecutive year. Among the top 100 Chinese companies with the greatest growth potential, Qizheng Tibetan Medicine ranked 27th, placing fifth among listed pharmaceutical companies.
It is understood that in compiling the list, the Chinese edition of Forbes adhered to its established criteria for evaluating potential enterprises: small and medium-sized enterprises with 2012 sales ranging from RMB 10 million to RMB 1 billion and whose primary business operations are based in mainland China. The ranking was determined based on growth indicators (growth rate and net profit growth rate) over the past three years (2010–2012), profitability indicators (sales profit margin), return-on-investment indicators (total asset return rate and net asset return rate), and scale indicators (total sales revenue and net profit). In addition, drawing on extensive enterprise data, the Chinese edition of Forbes conducted on-site visits to a number of outstanding candidate companies, ultimately selecting 100 listed and 100 unlisted enterprises.
The ranking shows that industries such as the internet and mobile internet, software technology, clean technology, healthcare, electronic information, consumer goods, and entertainment & media are leading the way. The internet has become a powerful driver of high business growth, with the mobile internet showing the most rapid development momentum. Meanwhile, the share of traditional manufacturing continues to decline. Additionally, as urbanization progresses and the population ages, entrepreneurial and growth opportunities in the healthcare and consumer sectors remain robust.
As of the end of 2012, our company had total assets of 1.433 billion yuan and owner’s equity of 1.321 billion yuan. We achieved total operating revenue of 934 million yuan and total profit of 223 million yuan. Our total number of employees exceeded 1,300, and we have cumulatively paid over 729 million yuan in taxes in the Tibet region. The company’s core business focuses on the inheritance and innovation of traditional Tibetan medicine. At the same time, in response to the development needs of our core business, we are vigorously promoting the research and marketing of large-health brand products that highlight resources from Tibet and the northwest region. We are particularly focused on building a fully traceable industrial chain for locally sourced medicinal materials from the northwest region and an industrial chain for health and wellness products from the Qinghai-Tibet Plateau. We are intensifying efforts to integrate internal and external resources, enhancing our overall competitiveness and industry standing. We are committed to fostering three major related industrial sectors—pharmaceuticals, medicinal materials, and health and wellness products—and gradually transitioning toward a business structure that synergistically integrates these diverse businesses with our core Tibetan medicine operations.
In the future, the company will remain committed to its core values of “doing good and benefiting others, pursuing integrity and excellence in our profession,” and uphold its mission of “spreading wisdom and caring for health.” Guided by the 2013-2015 strategic plan, the company will continue to enhance its capabilities in six key areas: inheritance, innovation, brand strength, marketing prowess, execution ability, and cultural vitality. We will steadily advance our transformation from a pharmaceutical company to a comprehensive healthcare enterprise, thereby fulfilling our mission and vision of becoming a modern Tibetan medicine and health industry group that provides natural solutions for the physical and mental well-being of humanity.